RareResearch.AI
← Back to atlas

A433T

Category 4 — Stable Fold, Function DisruptedUncertain significanceTransmembrane · predictedSource card
AlanineThreonine at position 433 · Transmembrane helix 5 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type A433 — hydrogen bond to T436
Fullscreen ↗
DynaMut2 mutant · A433T
Mutant T433 — hydrogen bond to T436 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost7 gained10 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondC429C429Preserved
Hydrogen bondS430Gained
Hydrogen bondT436T436Preserved
Hydrogen bondG437G437Preserved
Hydrogen bondI547Gained
Polar contactC429C429Preserved
Polar contactE431E431Preserved
Polar contactT436T436Preserved
Polar contactG437G437Preserved
Polar contactI547Gained
Polar contactL548Gained
Van der WaalsC429Lost
Van der WaalsE431E431Preserved
Van der WaalsI435Gained
Van der WaalsT436T436Preserved
Van der WaalsL548Gained
HydrophobicI547Lost
HydrophobicL548Gained
HydrophobicL556L556Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.81kcal/mol
Destabilising — moderate
AlphaMissense
0.342
ambiguous
AlphaFold pLDDT
91
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsInborn genetic diseases; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram syndrome 1; Cataract 41; Wolfram-like syndrome
Population frequency (gnomAD v4)Low frequency · AF 0.017%
cDNA changec.1297G>A
ClinVar accessionVCV000166587
Last evaluated2025/03/05 00:00

Observed in the general population.

Full Variant Card

WFS1 Wolframin — A433T Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Alanine → Threonine at position 433. Transmembrane helix 5. ClinVar Uncertain significance, AlphaMissense 0.342, DynaMut2 ΔΔG -1.81 kcal/mol (destabilising).


Identity

FieldValue
VariantA433T (p.Alanine433Threonine)
DNA changec.1297G>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV000166587
Amino acid changeAlanine (A) → Threonine (T)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 43391.31 — well-folded
DomainTransmembrane helix 5
Position contextInside Transmembrane helix 5 · position 433 is bilayer-embedded
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 433 sits in a transmembrane helix (Transmembrane helix 5). Wolframin has eleven such helices anchoring it in the ER membrane; substitutions inside the bilayer-embedded segments can disrupt helix packing, lipid contacts, and the overall ER topology of the protein. The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small polar (threonine — hydroxyl). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.3415
am_classambiguous
InterpretationLikely benign (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-1.81 (Destabilising)
Job ID178094708212
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178094708212

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2025/03/05 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeA433T is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Inborn genetic diseases
  • Autosomal dominant nonsyndromic hearing loss 6
  • Type 2 diabetes mellitus
  • Wolfram syndrome 1
  • Cataract 41
  • Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 4 — Stable Fold, Function Disrupted

<strong>Category 4 — Stable Fold, Function Disrupted</strong><br/><br/>|ΔΔG|=1.81 negligible. Likely site-specific functional disruption — docking strategy.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.81 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.342. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • A433T_molstar_viewer.html — interactive 3D viewer (auto-highlights position 433 with ball-and-stick + neighbors within 5Å)
  • A433T_variant_card.md — this card (source of truth)
  • A433T_variant_card.html — styled printable card
  • A433T_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • A433T_wildtype_interactions.pse / A433T_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A433T PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A433T PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.